Screener
Organon OGN Int’l — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
| ($ in millions) | Three Months Ended March 31, 2025 / U.S. | 2025 / Int’l | Total | U.S. | Int’l | Total |
|---|---|---|---|---|---|---|
| Other Non-Opioid Pain, Bone and Dermatology (1) | 3 | 65 | 68 | 4 | 65 | 68 |
| Other | ||||||
| Propecia | 1 | 28 | 30 | 1 | 24 | 26 |
| Emgality | — | 54 | 54 | — | 32 | 32 |
| Proscar | — | 26 | 26 | — | 24 | 24 |
| Other (1) | 3 | 85 | 87 | 3 | 76 | 78 |
| Other (2) | — | 18 | 18 | — | 22 | 22 |
| Revenues | $358 | $1,102 | $1,460 | $412 | $1,101 | $1,513 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Organon's int’l — revenue?
- Organon (OGN) reported int’l — revenue of $1.1B in Q1 2026.
- How has Organon's int’l — revenue changed year-over-year?
- Organon's int’l — revenue increased by 0.1% year-over-year, from $1.1B to $1.1B.
- What is the long-term trend for Organon's int’l — revenue?
- Over 4 years (2021 to 2025), Organon's int’l — revenue has grown at a -1.6% compound annual growth rate (CAGR), from $4.92B to $4.61B.
- What does int’l — revenue mean?
- This metric represents the total gross revenue generated from the sale of pharmaceutical products, including women's health, biosimilars, and established brands, within international geographic markets. It serves as a primary indicator of the company's market penetration and commercial performance outside of its domestic base. Tracking this figure allows investors to assess the growth trajectory and demand stability of the company's global product portfolio.
Ask your AI about Organon's int’l — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude